Gene and Cell Therapy for Heart Failure
- 1 August 2009
- journal article
- review article
- Published by Mary Ann Liebert Inc in Antioxidants and Redox Signaling
- Vol. 11 (8), 2025-2042
- https://doi.org/10.1089/ars.2009.2495
Abstract
Cardiac gene and cell therapy have both entered clinical trials aimed at ameliorating ventricular dysfunction in patients with chronic congestive heart failure. The transduction of myocardial cells with viral constructs encoding a specific cardiomyocyte Ca2+ pump in the sarcoplasmic reticulum (SR), SRCa2+-ATPase has been shown to correct deficient Ca2+ handling in cardiomyocytes and improvements in contractility in preclinical studies, thus leading to the first clinical trial of gene therapy for heart failure. In cell therapy, it is not clear whether beneficial effects are cell-type specific and how improvements in contractility are brought about. Despite these uncertainties, a number of clinical trials are under way, supported by safety and efficacy data from trials of cell therapy in the setting of myocardial infarction. Safety concerns for gene therapy center on inflammatory and immune responses triggered by viral constructs, and for cell therapy with myoblast cells, the major concern is increased incidence of ventricular arrhythmia after cell transplantation. Principles and mechanisms of action of gene and cell therapy for heart failure are discussed, together with the potential influence of reactive oxygen species on the efficacy of these treatments and the status of myocardial-delivery techniques for viral constructs and cells. Antioxid. Redox Signal. 11, 2025–2042.Keywords
This publication has 144 references indexed in Scilit:
- p66Shc Links α 1 -Adrenergic Receptors to a Reactive Oxygen Species-Dependent AKT-FOXO3A Phosphorylation Pathway in CardiomyocytesCirculation Research, 2009
- Redox Modification of Ryanodine Receptors Contributes to Sarcoplasmic Reticulum Ca 2+ Leak in Chronic Heart FailureCirculation Research, 2008
- Gene Therapy in Heart FailureCirculation Research, 2008
- Optimized Lentiviral Transduction of Mouse Bone Marrow-Derived Mesenchymal Stem CellsStem Cells and Development, 2008
- Adult Bone Marrow–derived Cells Do Not Acquire Functional Attributes of Cardiomyocytes When Transplanted into Peri-infarct MyocardiumMolecular Therapy, 2008
- Origins and Fates of Cardiovascular Progenitor CellsCell, 2008
- Human cardiac stem cellsProceedings of the National Academy of Sciences, 2007
- Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repairProceedings of the National Academy of Sciences, 2007
- Hematopoietic Stem CellsMethods in enzymology, 2006
- Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiationNature Medicine, 2004